![Sylvie le Gledic](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sylvie le Gledic
Geen lopende functies
Profiel
Sylvie le Gledic worked as a Director of Development & Regulatory Affairs at BioSystems International SAS.
She holds a doctorate degree from Université Paris 1 Panthéon-Sorbonne.
Eerdere bekende functies van Sylvie le Gledic
Bedrijven | Functie | Einde |
---|---|---|
BioSystems International SAS
![]() BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | Algemeen Adviseur | 06-03-2014 |
Opleiding van Sylvie le Gledic
Université Paris 1 Panthéon-Sorbonne | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
BioSystems International SAS
![]() BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | Health Technology |